Welcome to MorphoSys

Founded some 20 years ago, MorphoSys is today one of the world's leading biotechnology companies. From a pure antibody platform enterprise, MorphoSys has matured into a renowned biopharmaceutical company with a rich pipeline of future therapeutic antibody products and a sustainable dual therapeutic business model. The Company’s aim is to continue pushing the boundaries of antibody generation in the industry – to engineer the medicines of tomorrow.


Innovation Capital

A new initiative through which MorphoSys provides innovation capital to promising start-ups.


H1 2014 Report

Have a look at MorphoSys's Six Months' Report 2014



  • 20/10/2014 // MorphoSys Announces Clinical Milestone in Ophthalmology Program

    more …

  • 15/10/2014 // MorphoSys Acquires Lanthipeptide Technology from Lanthio Pharma

    more …

Find more releases in the news overview


MorphoSys is interested in antibodies and biologics at late preclinical or early clinical stages.


Media & Investors

The latest company news for media representatives and the financial community.